Abstract
Alzheimer’s disease (AD) is the most common cause of dementia, with global case numbers projected to reach 153 million in 20501. AD is highly heritable, with twin-based heritability estimates of 60-80%2. While 1,200 causal loci are predicted to exist for AD3, approximately 80 have been associated with AD in two recent studies4,5, suggesting that many loci remain to be discovered6. Here, we analyzed data from 109,479 cases, 74,141 proxy cases, 2,131,799 controls, and 499,708 proxy controls from diverse ancestries, identifying 118 loci in a multi-ancestry analysis and 9 additional loci in ancestry-specific analyses, 48 of which are new. We identified new AD risk genes, prioritized potential drug targets, and identified microglia and, for the first time, several neuronal cell types enriched for AD-associated genetic risk. Moreover, we improved polygenic prediction and estimated a single-nucleotide polymorphism (SNP) heritability of 16%. Together, our findings offer insights into the genetic architecture and potential pathobiology of AD, as well as specific targets for future drug development research.
Competing Interest Statement
DR served as consultant for Boehringer-Ingelheim and Janssen, received honoraria from Boehringer-Ingelheim, Gerot Lannacher, Indorsia, Janssen and Pharmagenetix, received research/ travel support from Angelini, Boehringer-Ingelheim, Janssen and Schwabe, and served on advisory boards of AC Immune, Boehringer-Ingelheim, Indorsia, Roche and Rovi. SJvdL is part of the GeneMINDS consortium, which is powered by Health∼Holland, Top Sector Life Sciences & Health and receives co-financing from Vigil Neuroscience, Prevail therapeutics and Brain Research Center. All funding is paid to his institution. WMvdF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. All funding is paid to her institution. WMvdF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, Eisai, Eli-Lilly, Owkin France, Nationale Nederlanden Ventures. All funding is paid to her institution. WMvdF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. WMvdF is member of the steering committee of phase 3 EVOKE/EVOKE+ studies (NovoNordisk). WMvdF is member of the steering committee op phase 3 Trontinemab study (Roche). All funding is paid to her institution. WMvdF is member of the steering committee of PAVE, and Think Brain Health. WMvdF is chair of the Scientific Leadership Group of InRAD. WMvdF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WMvdF is associate editor at Brain. WMvdF is member of Supervisory Board (Raad van Toezicht) Trimbos Instituut. ChB and AM are holders of Roche stock. AHS received a one-time consulting fee, paid to the institution from Eisai / BioArctic (2025) SK has served at scientific advisory boards, speaker and / or as consultant for Roche, Eli Lilly, Geras Solutions, Optoceutics, Biogen, Eisai, Merry Life, Triolab, Novo Nordisk and Bioarctic, unrelated to present study content. JB is an employee of Roche. GS has participated in Advisory Board meetings for Roche, Eli-Lilly and Eisai regarding disease-modifying drugs for Alzheimer's disease. GS has received honoraria for delivering lectures at symposia sponsored by Eisai and Eli-Lilly. BEK has previously served on an advisory board for Eisai and as a consultant for Biogen. He is currently a consultant and advisory board member for Eli Lilly. OF is a consultant to Precision Health. BH is employed by Eli Lilly and Company and owns publicly traded stocks of this company.
Funding Statement
This project was supported by the NWO Gravitation grant BRAINSCAPES: a roadmap from neurogenetics to neurobiology (grant no. 024.004.012), the European Research Council Advanced Grant (grant no. ERC-2018-ADG 834057), the Research Council of Norway (grants #344121, #324499, and #353629), the European Union's Horizon 2020 Research and Innovation Action (grant #964874), NordForsk (grant #164218), and the NIMH (award 5R01MH124839-05). Acknowledgements for each cohort can be found in the Supplementary Info.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was provided by the cohorts contributing samples. HUNT: The current study is approved by the Regional Committee for Medical and Health Research Ethics (ref. 2017/1031). Estionian Biobanks: Individual-level data analysis in the EstBB was carried out under ethical approval 1.1-12/624 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs) using data according to the release application 6-7/GI/18759 from the Estonian Biobank. DBDS: DBDS is a nationwide study of ∼170,000 blood donors, approved by The Danish Data Protection Agency (P-2019-99) and the National Committee on Health Research Ethics (NVK-1700407). CHB: The study was approved by the National Scientific Ethical Committee and the Capital Region Data Protection Office (H-21058057 and P-2022-392) DeCODE: Approval for this study was obtained from the National Bioethics Committee and the Icelandic Data Protection Authority (VSN-19-129). Lifelines: The Lifelines protocol was approved by the UMCG Medical Ethics Committee under number 2007/152. UK Biobank: The UKB received ethical approval from the National Research Ethics Service Committee North West-Haydock (reference 11/NW/0382). PMBB: The PMBB is approved under IRB protocol# 813913 CCPM: All samples and data were collected under Institutional Review Board (IRB) approved protocol (#15-0461) with appropriate informed consent from participants. BioBank Japan: All participants provided written informed consent as approved by the ethical committees of the RIKEN Center for Integrative Medical Sciences and the Institute of Medical Sciences at the University of Tokyo. DemGene: The current study was approved by REC# 2014/631
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This revised version addresses peer-review comments received on the previous version. The principal changes are as follows. Gene prioritization. We have substantially extended our analyses to prioritize a small set of genes causally implicated in Alzheimer's disease, each with experimentally testable hypotheses. By combining colocalization with Mendelian randomization, cell-type enrichment, and differential expression, we now assign prioritized genes to a specific cell type, biological process, and hypothesized direction of effect. The results implicate astrocytes and oligodendrocytes alongside the established microglial and neuronal contributions, and are presented in a new Results section. Heritability estimation. We added simulation analyses comparing heritability estimates from SBayesRC and LD-Score Regression (LDSC) in a scenario with known ground truth. These highlighted a severe downward bias of LDSC under a major-gene architecture, as in Alzheimer's disease, and revealed a small upward bias in SBayesRC that was easily corrected, yielding a new European estimate of 16 percent (compared with 6 percent from LDSC, the field standard). Figure 4 has been updated accordingly. Proxy-case sensitivity analyses. We conducted numerous sensitivity analyses for the inclusion of proxy cases, showing that it does not bias our results but instead substantially increases statistical power. All sets of summary statistics will be made publicly available with and without proxy cases. Additional sensitivity analyses. We conducted further sensitivity analyses to address concerns about phenotype definition, meta-analysis approach, and cohort-level covariate adjustment. Excluding cohorts that used ICD-10 code F03 (unspecified dementia) did not attenuate pleiotropic correlations with other neurodegenerative diseases. A random-effects meta-analysis with METASOFT yielded results nearly identical to our fixed-effects analysis. Excluding three cohorts that did not correct for batch or array reduced power but did not introduce false-positive signals. Several supplementary figures, tables, and notes have been added, and extensive textual revisions have been made throughout the manuscript. Taken together, these revisions sharpen the prioritization of causal genes and biological mechanisms, refine our heritability estimates through simulation-based validation, and demonstrate the robustness of our findings across a wide range of sensitivity analyses.
Data availability
Summary statistics will be made available upon acceptance.
